Trial | NCT04579640  Report issue

Title

Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections
Phase 3 Randomised Controlled Trial of Vitamin D Supplementation to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections in the UK Population

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    6200
CORONAVIT is an open-label, phase 3, randomised clinical trial testing whether implementation of a test-and-treat approach to correction of sub-optimal vitamin D status results in reduced risk and/or severity of COVID-19 and other acute respiratory infections.
Study Started
Oct 27
2020
Primary Completion
Jun 17
2021
Study Completion
Feb 28
2022
Last Update
Apr 06
2022

Dietary Supplement Vitamin D

Capsules containing 800 IU (20 micrograms) or 3,200 IU (80 micrograms) cholecalciferol

Control No Intervention

Standard of care (national recommendation of 400 IU/day vitamin D)

Intervention: Lower-dose vitamin D Experimental

Offer of a daily dose of 800 IU (20 micrograms) cholecalciferol to individuals with 25-hydroxyvitamin D level <75 nmol/L

Intervention: Higher-dose vitamin D Experimental

Offer of a daily dose of 3200 IU (80 micrograms) cholecalciferol to individuals with 25-hydroxyvitamin D level <75 nmol/L

Criteria 

Inclusion criteria:

UK resident
Age ≥16 years
Gives informed consent to participate

Exclusion criteria:

taking digoxin, alfacalcidol, calcitriol, dihydrotachysterol or paricalcitol
known diagnosis of sarcoidosis, primary hyperparathyroidism, renal stones or renal failure requiring dialysis
known allergy to any ingredient in the study capsules (vitamin D, olive oil, caramel, gelatine or glycerol)
pregnancy
No Results Posted